Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03697512
Title MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas (MALIBU)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors International Extranodal Lymphoma Study Group (IELSG)

nodal marginal zone lymphoma

marginal zone B-cell lymphoma

splenic marginal zone lymphoma

MALT lymphoma


Ibrutinib + Rituximab

Age Groups: senior | adult
Covered Countries ITA | FRA | BEL

No variant requirements are available.